Jupiter Neurosciences Inc JUNS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.17
- Day Range
- $0.16–0.24
- 52-Week Range
- $0.16–1.85
- Bid/Ask
- $0.17 / $0.17
- Shares Outstanding
- 48.22M
- Market Cap
- $8.18M
- Volume/Avg
- 351M / 7M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 143.48
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
Valuation
|
Metric
|
JUNS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 143.48 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
JUNS
|
|---|---|
Quick Ratio | 0.35 |
Current Ratio | 0.51 |
Interest Coverage | −49.08 |
Quick Ratio
JUNS
Profitability
|
Metric
|
JUNS
|
|---|---|
Return on Assets (Normalized) | −158.93% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −307.52% |
Return on Assets
JUNS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|R?^S!d? | LOCK|&%K> | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|wg#vd>b | LOCK|tkVQ | $70B | |||
| argenx SE ADR
ARGX
| LOCK|&@St>Ty | LOCK|V^ | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Xln@R& | LOCK|VM# | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|N@^s&n^ | LOCK|?TP& | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|V$T?>B% | LOCK|Mqjz | $25B | |||
| Moderna Inc
MRNA
| LOCK|l<<%sT | LOCK|jMw | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|yTtYy< | LOCK|CJ& | $23B | |||
| Incyte Corp
INCY
| LOCK|y?&gg^ | LOCK|z$? | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|?C!Fwq< | LOCK|>!S | $16B |
United States